Form 4: Precision Biosciences Director Kevin Buehler Reports RSU Vesting and New Equity Grant

Precision Biosciences Director Kevin Buehler has reported the vesting of 9,826 Restricted Stock Units (RSUs) and the acquisition of 21,000 new RSUs, aligning his interests with the company's long-term performance.

Summary

• On May 27, 2025, Kevin Buehler, a Director of Precision Biosciences Inc. (DTIL), reported the vesting of 9,826 Restricted Stock Units (RSUs), which converted into 9,826 shares of Common Stock.
• These RSUs were originally granted on June 4, 2024, and vested based on the earlier of June 4, 2025, or the day prior to the Issuer's next annual meeting, subject to continued service.
• Following this transaction, Kevin Buehler beneficially owns 23,061 shares of Common Stock directly.
• Additionally, on June 3, 2025, Mr. Buehler was granted 21,000 new Restricted Stock Units (RSUs).
• These new RSUs are scheduled to vest on the earlier of June 3, 2026, or the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, contingent on his continued service to the Issuer.
• After the new grant, Mr. Buehler directly holds 21,000 unvested Restricted Stock Units.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's a routine compensation event, the continued grant of equity to a director suggests ongoing commitment and alignment with the company's future, which is generally viewed favorably.

Positives

• The grant of new Restricted Stock Units to Director Kevin Buehler indicates continued alignment of management's interests with shareholder value through equity compensation.
• The vesting of previous RSUs demonstrates the company's commitment to its equity compensation plans for directors.

Risks

• The vesting of both the previously granted and newly granted Restricted Stock Units is subject to Kevin Buehler's continued service to Precision Biosciences Inc. through the applicable vesting dates.

Future Outlook

The newly granted 21,000 Restricted Stock Units are expected to vest on the earlier of June 3, 2026, or the day prior to the Issuer's next annual meeting of stockholders, contingent upon the director's continued service.

Industry Context

This Form 4 filing details a routine insider transaction related to equity compensation for a director, which is a common practice across publicly traded companies to align management and board interests with shareholder value. It does not provide broader industry trends or competitive insights.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• The 21,000 Restricted Stock Units granted on June 3, 2025, are anticipated to vest on the earlier of June 3, 2026, or the day immediately prior to the Issuer's next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

Precision Biosciences, DTIL, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Equity Compensation, Director Compensation, Stock Vesting, Stock Grant